Advancing Multiple Programs in Areas of Significant Unmet Medical NeedSeveral Milestones Across Clinical Development Pipeline Expected in ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AMLSAN DIEGO and ...

Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...